ArticleEuropean radiology2015
Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance.
Article in European radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Comparison of single-shot EPI and multi-shot EPI in prostate DWI at 3.0 T.Scientific reports · 2022Article
- Diffusion-weighted imaging in prostate cancer.Magma (New York, N.Y.) · 2022Review
- Assessment of magnetic resonance imaging (MRI)-fusion prostate biopsy with concurrent standard systematic ultrasound-guided biopsy among men requiring repeat biopsy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Active Surveillance of Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: A Review of the Current Role and Future Perspectives.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
- Radiological semantics discriminate clinically significant grade prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
- Signal Intensity of High B-value Diffusion-weighted Imaging for the Detection of Prostate Cancer.Journal of biomedical physics & engineering · 2019Article
- A negative multiparametric magnetic resonance imaging finding does not guarantee the absence of significant cancer among biopsy-proven prostate cancer patients: a real-life clinical experience.International urology and nephrology · 2018Article
- MRI findings guiding selection of active surveillance for prostate cancer: a review of emerging evidence.Translational andrology and urology · 2018Review
- The impact of computed high b-value images on the diagnostic accuracy of DWI for prostate cancer: A receiver operating characteristics analysis.Scientific reports · 2018Article
- Magnetic resonance imaging in active surveillance-a modern approach.Translational andrology and urology · 2018Review
- Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU).Wiener klinische Wochenschrift · 2017Article
- Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.Abdominal radiology (New York) · 2017Article
- Impact of post-processing methods on apparent diffusion coefficient values.European radiology · 2017Article
- Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance.Frontiers in oncology · 2017Review
- 25th Anniversary of European Radiology.European radiology · 2017Article
- Article
- Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?World journal of urology · 2016Article
- Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.European urology · 2016Article
- Current status of active surveillance in prostate cancer.Investigative and clinical urology · 2016Review
- Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.Korean journal of urology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate whether the apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) could help improve the prediction of insignificant prostate cancer in candidates for active surveillance (AS).
methodsEnrolled in this retrospective study were 287 AS candidates who underwent DW-MRI before radical prostatectomy. Patients were stratified into two groups; Group A consisted of patients with no visible tumour or a suspected tumour ADC value > 0.830 × 10(-3) mm(2)/sec and Group B consisted of patients with a suspected tumour ADC value < 0.830 × 10(-3) mm(2)/sec. We compared pathological outcomes in each group.
resultsGroup A had 243 (84.7 %) patients and Group B had 44 (15.3 %) patients. The proportion of organ-confined Gleason ≤ 6 disease and insignificant prostate cancer was significantly higher in Group A than Group B (61.3 % vs. 38.6 %, p = 0.005 and 47.7 % vs. 25.0 %, p = 0.005, respectively). On multivariate analysis, a high ADC value was the independent predictor of organ-confined Gleason ≤ 6 disease and insignificant prostate cancer (odds ratio = 2.43, p = 0.011 and odds ratio = 2.74, p = 0.009, respectively).
conclusionTumour ADC values may be a useful marker for predicting insignificant prostate cancer in candidates for AS. KEY POINTS: • ADC from DW-MRI can help assess prostate cancer aggressiveness in potential AS candidates. • There was a closed correlation between higher ADC values and insignificant prostate cancer. • The absence of lesions on DWI/DWI can help select potential AS candidates.
Indexed as
Identifiers
25636416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.